SARS-CoV-2 Spike full length, G614

Reference:
Size

100ug, 50ug

Brand

Product type

Host Species

Product nameSARS-CoV-2 Spike full length, G614
Origin speciesSARS-COV2
Expression systemEukaryotic expression
Molecular weight136kDa
Purity estimated>90%
BufferPBS, pH7.5
FormLiquid
Delivery conditionDry Ice
Storage condition4°C for short term; -20°c or -80°C for long term
BrandProteoGenix
Host speciesMammalian cells
ApplicationsELISA,WB
Fragment TypeFull length
ReferencePX-COV-P051
NoteFor research use only. Not suitable for human use.

Description of SARS-CoV-2 Spike full length, G614

General information on SARS-CoV-2 Spike full length (variant 3), G614

The spike glycoprotein is the most important antigen in the pandemic strain of coronavirus, SARS-CoV-2, the causative agent of the COVID-19 respiratory disease. Containing a complex transmembrane domain and exposed on a trimeric form on the surface of the new virus, the spike protein can be divided into subunits S1 and S2 linked by a furin cleavage site. The S1 subunit contains the receptor-binding domain (RBD) that binds the human receptor ACE2, enriched on the surface of upper respiratory tract epithelial cells. As a consequence, the formation of the RBD-ACE2 complex is known to drive the proteolytic cleavage of the spike, exposing the S2 subunit. As a result, the S2 suffers important molecular rearrangements leading to membrane fusion and virion internalization. To render the spike proteinase-stable, specific single point mutations were made to the furin cleavage linker sequence. In this way, it became possible to express a stable version of the spike with prolonged shelf-life, a crucial change that allows the development of research, diagnostics, and therapeutic applications. The D614G mutation to the spike was first detected in Europe in early March, and it corresponds to a single nucleotide change (G-to-A on position 23,403) that rendered the spike more flexible than the early variant and consequently enhanced its infectivity. Due to its enhanced properties, the variant G614, also known as the “G” clade, became the dominant version of the spike protein in SARS-CoV-2 by the end of March 2020 on a global scale. Further studies revealed the D614G mutation may also enhance not only the stability of virions but also their fitness and replication. This specific version of the spike is monomeric and expressed in Chinese hamster ovary (CHO) cells with high quality and purity. The spike can thus serve as a control for standard detection tests (e.g. ELISA, Flow Cytometry, WB, etc.). Moreover, due to its vital role in the early stages of infection, this protein continues to guide the development of new diagnostic tools, biotherapeutics, and vaccines.

Related products:

SDS-PAGE for SARS-CoV-2 Spike full length, G614 Recombinant proteins

Publication

Masih Alam, Rawshan Choudhury, Robert-Jan Lamers, An adaptable in vitro cytokine release assay (CRA): Susceptibility to cytokine storm in COVID-19 as a model, Current Research in Immunology, Volume 3, 2022, Pages 239-243, ISSN 2590-2555, https://doi.org/10.1016/j.crimmu.2022.11.001.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “SARS-CoV-2 Spike full length, G614”

Your email address will not be published. Required fields are marked *

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.






    Cart (0 Items)

    Your cart is currently empty.

    View Products